



ANDA 202912

Lupin Pharmaceuticals, Inc.
U.S. Agent for: Lupin Limited
Attention: Leslie Sands
Director, Regulatory Affairs
Harborplace Tower
111 South Calvert Street, 21st Floor
Baltimore, MD 21202

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated March 22, 2011, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base)/150 mg/300 mg.

Reference is also made to the Complete Response letter issued by this office on July 10, 2013; and your amendments dated July 15, and November 29, 2013.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base)/150 mg/300 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Trizivir Tablets, 300 mg (base)/150 mg/300mg, of ViiV Healthcare (ViiV). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

The RLD upon which you have based your ANDA, ViiV's Trizivir Tablets is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the agency's publication titled Approved Drug Products with Therapeutic

Equivalence Evaluations (the "Orange Book") for this drug product:

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
5,905,082 (the '082 patent)	November 18, 2016
6,294,540 (the '540 patent)	November 14, 2018
6,417,191 (the '191 patent)	September 28, 2016

With respect to each of these patents, your ANDA contains a paragraph IV certification under section 505(j)(2)(A)(vii)(IV) of the Act stating that each patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base)/150 mg/300 mg, under this ANDA. You have notified the agency that Lupin Limited (Lupin) complied with the requirements of section 505(j)(2)(B) of the Act, and that litigation was initiated against Lupin for infringement of the '191 patent within the statutory 45-day period in the United States District Court for the District of Delaware [ViiV Healthcare UK Ltd., and ViiV Healthcare Co., v. Lupin Ltd., and Lupin Pharmaceuticals, Inc., Civil Action No. 11-CV-00576-RGA]. Although this litigation remains ongoing, the 30-month period identified in section 505(j)(5)(B)(iii) of the Act, during which time FDA was precluded from approving your ANDA, has expired.

With respect to 180-day generic drug exclusivity, we note that Lupin was the first applicant to submit a substantially complete ANDA with a paragraph IV certification to one or more of the listed patents. Therefore, with this approval, Lupin is eligible for 180 days of generic drug exclusivity for Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base)/150 mg/300 mg. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the Act, will begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA informing the agency of the date the exclusivity begins to run.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR

314.50(1)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Kathleen Uhl, M.D.
Acting Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

12/05/2013

Deputy Director, Office of Generic Drugs, for
Kathleen Uhl, M.D.